Cargando…

Premature Death in Bodybuilders: What Do We Know?

Premature deaths in bodybuilders regularly make headlines and are cited as evidence that bodybuilding is a dangerous activity. A wealth of research has revealed elite athletes typically enjoy lower mortality rates than non-athletes, but research on bodybuilder lifespan is surprisingly limited. Anabo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smoliga, James M., Wilber, Z. Taggart, Robinson, Brooks Taylor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Current Opinion
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885939/ https://www.ncbi.nlm.nih.gov/pubmed/36715876 http://dx.doi.org/10.1007/s40279-022-01801-0

Ejemplares similares

What Do We Know About Youth Softball Pitching and Injury?
por: Barfield, Jeff, et al.
Publicado: (2018)

Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?
por: Plocque, Alexia, et al.
Publicado: (2022)

Transmission of Ebola Viruses: What We Know and What We Do Not Know
por: Osterholm, Michael T., et al.
Publicado: (2015)

Do Non-Responders to Exercise Exist—and If So, What Should We Do About Them?
por: Pickering, Craig, et al.
Publicado: (2018)

What Should We Do About Habitual Caffeine Use in Athletes?
por: Pickering, Craig, et al.
Publicado: (2018)

Big Tau: What We Know, and We Need to Know
por: Fischer, Itzhak
Publicado: (2023)

‘Knowing as we go’: a Hunter-Gatherer Behavioural Model to Guide Innovation in Sport Science
por: Woods, Carl T., et al.
Publicado: (2020)

Mpox and Monkeypox Virus: Special Considerations for Athletes in Contact Sports
por: Smoliga, James M.
Publicado: (2023)

Spectrum of MRI findings of foetal alcohol syndrome disorders—what we know and what we need to know!
por: Sharif, Saad, et al.
Publicado: (2023)

COVID-19 and the liver: What do we know after six months of the pandemic?
por: Fierro, Nora A.
Publicado: (2020)

COVID-19 and the liver: What do we know so far?
por: Nasa, Prashant, et al.
Publicado: (2021)

Cardiac surgery and the coronavirus disease 2019 pandemic: What we know, what we do not know, and what we need to do
por: Bakaeen, Faisal G., et al.
Publicado: (2020)

Interpreting troponin elevations: do we need multiple diagnoses?
por: Pierpont, Gordon L., et al.
Publicado: (2009)

What Do We Really Know about How CD4 T Cells Control Mycobacterium tuberculosis?
por: Torrado, Egidio, et al.
Publicado: (2011)

Moody microbes or fecal phrenology: what do we know about the microbiota-gut-brain axis?
por: Forsythe, Paul, et al.
Publicado: (2016)

Mass casualty events: what to do as the dust settles?
por: Russo, Rachel M, et al.
Publicado: (2018)

Language of violence: Do words matter more than we think?
por: Tatebe, Leah C, et al.
Publicado: (2022)

What Future Healthcare Professionals Need to Know About Pharmacovigilance: Introduction of the WHO PV Core Curriculum for University Teaching with Focus on Clinical Aspects
por: van Eekeren, Rike, et al.
Publicado: (2018)

Proximal femoral growth disturbance in developmental dysplasia of the hip: what do we know?
por: Weinstein, S. L., et al.
Publicado: (2018)

Cell Therapy of Severe Ischemia in People with Diabetic Foot Ulcers—Do We Have Enough Evidence?
por: Dubský, Michal, et al.
Publicado: (2023)

Mini-Review: Role of Drugs Affecting Renin-Angiotensin System (RAS) in Traumatic Brain Injury (TBI): What We Know and What We Should Know
por: Sarpolaki, Mohammad Kazem, et al.
Publicado: (2023)

Bracing in clubfoot: do we know enough?
por: Alves, C.
Publicado: (2019)

Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?
por: Goldsmith, David, et al.
Publicado: (2018)

Quasicrystals: What do we know? What do we want to know? What can we know?
por: Steurer, Walter
Publicado: (2018)

Developing Decision-Making Expertise in Professional Sports Staff: What We Can Learn from the Good Judgement Project
por: Wilson, P. J., et al.
Publicado: (2023)

Vaccinations in Patients Receiving Systemic Drugs for Skin Disorders: What Can We Learn for SARS-Cov-2 Vaccination Strategies?
por: Speeckaert, Reinhart, et al.
Publicado: (2021)

What do we know and when do we know it?
por: Nicholls, Anthony
Publicado: (2008)

Presbyopia: What We Do Know and What We Do Not Know in 2022
por: Grzybowski, Andrzej, et al.
Publicado: (2023)

Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour?
por: Atal, Shubham, et al.
Publicado: (2020)

Vaginal Aging—What We Know and What We Do Not Know
por: Szymański, Jacek K., et al.
Publicado: (2021)

COVID-19 and cancer: do we really know what we think we know?
por: Robinson, Andrew G., et al.
Publicado: (2020)

Giant paraesophageal hernia: What do we really know?
por: Bhargava, Amit, et al.
Publicado: (2020)

Manifesto on the Value of Adult Immunization: “We Know, We Intend, We Advocate”
por: Antonelli-Incalzi, Raffaele, et al.
Publicado: (2021)

Dead Bodybuilders Speaking from the Heart: An Analysis of Autopsy Reports of Bodybuilders That Died Prematurely
por: Escalante, Guillermo, et al.
Publicado: (2022)

Multimorbidity: What do we know? What should we do?
por: Navickas, Rokas, et al.
Publicado: (2016)

Complement Inhibition in Kidney Transplantation: Where Are We Now?
por: Vonbrunn, Eva, et al.
Publicado: (2022)

Opinion: To assess marine cloud brightening's technical feasibility, we need to know what to study—and when to stop
por: Diamond, Michael S., et al.
Publicado: (2022)

Antibiotics, obesity and the link to microbes - what are we doing to our children?
por: Turta, Olli, et al.
Publicado: (2016)

Cerebrospinal fluid circulation: What do we know and how do we know it?
por: Khasawneh, Ahmad H, et al.
Publicado: (2018)

Health Inequalities: To What Extent are Decision-Makers and Economic Evaluations on the Same Page? An English Case Study
por: Hinde, Sebastian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l65r5ppnjntuvocf4u7j2hd5ma